Pooresmaeil F, Azadi S, Hasannejad-Asl B, Takamoli S, Bolhassani A
Mol Biotechnol. 2024; .
PMID: 39673006
DOI: 10.1007/s12033-024-01343-y.
Aravindraja C, Jeepipalli S, Duncan W, Vekariya K, Bahadekar S, Chan E
Int J Mol Sci. 2023; 24(22).
PMID: 38003583
PMC: 10671577.
DOI: 10.3390/ijms242216393.
Ghalkhani E, Akbari M, Izadi P, Mahmoodzadeh H, Kamali F
Iran J Public Health. 2023; 51(12):2808-2816.
PMID: 36742232
PMC: 9874213.
DOI: 10.18502/ijph.v51i12.11472.
Javdani H, Mollaei H, Karimi F, Mahmoudi S, Farahi A, Mirzaei-Parsa M
Mol Biol Rep. 2022; 49(10):9963-9973.
PMID: 35716288
DOI: 10.1007/s11033-022-07553-4.
Dong B, Li S, Zhu S, Yi M, Luo S, Wu K
Exp Hematol Oncol. 2021; 10(1):12.
PMID: 33579377
PMC: 7881653.
DOI: 10.1186/s40164-021-00206-5.
Interplay between p53 and non-coding RNAs in the regulation of EMT in breast cancer.
Parfenyev S, Singh A, Fedorova O, Daks A, Kulshreshtha R, Barlev N
Cell Death Dis. 2021; 12(1):17.
PMID: 33414456
PMC: 7791039.
DOI: 10.1038/s41419-020-03327-7.
Systems biology approach suggests new miRNAs as phenotypic stability factors in the epithelial-mesenchymal transition.
Silveira D, Gupta S, Mombach J
J R Soc Interface. 2020; 17(171):20200693.
PMID: 33050781
PMC: 7653381.
DOI: 10.1098/rsif.2020.0693.
The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu S, Li Y, Zhang H, Zhang D, Zhang X, Wang X
Theranostics. 2020; 10(23):10729-10742.
PMID: 32929377
PMC: 7482812.
DOI: 10.7150/thno.46297.
Potential miRNAs for miRNA-Based Therapeutics in Breast Cancer.
Wong J, Cheah Y
Noncoding RNA. 2020; 6(3).
PMID: 32668603
PMC: 7549352.
DOI: 10.3390/ncrna6030029.
Regulation of breast cancer metastasis signaling by miRNAs.
Petri B, Klinge C
Cancer Metastasis Rev. 2020; 39(3):837-886.
PMID: 32577859
PMC: 7487050.
DOI: 10.1007/s10555-020-09905-7.
Niao Du Kang Mixture Increases the Expression of mir-129-5p to Relieve Renal Fibrosis.
Li Y, Liu L, Huang L, An H, Jian J, Pang J
Evid Based Complement Alternat Med. 2020; 2020:1841890.
PMID: 32454849
PMC: 7222611.
DOI: 10.1155/2020/1841890.
Inhibition of ZEB1-AS1 confers cisplatin sensitivity in breast cancer by promoting microRNA-129-5p-dependent ZEB1 downregulation.
Gao J, Yuan Y, Zhang L, Yu S, Lu J, Feng J
Cancer Cell Int. 2020; 20:90.
PMID: 32210737
PMC: 7092489.
DOI: 10.1186/s12935-020-1164-8.
MiR-129-5p sensitization of lung cancer cells to etoposide-induced apoptosis by reducing YWHAB.
Xu C, Du Z, Ren S, Liang X, Li H
J Cancer. 2020; 11(4):858-866.
PMID: 31949489
PMC: 6959023.
DOI: 10.7150/jca.35410.
Prognostic role of microRNAs in breast cancer: A systematic review.
Zografos E, Zagouri F, Kalapanida D, Zakopoulou R, Kyriazoglou A, Apostolidou K
Oncotarget. 2020; 10(67):7156-7178.
PMID: 31903173
PMC: 6935258.
DOI: 10.18632/oncotarget.27327.
MicroRNA-129-5p suppresses nasopharyngeal carcinoma lymphangiogenesis and lymph node metastasis by targeting ZIC2.
Yu D, Han G, Zhao X, Liu X, Xue K, Wang D
Cell Oncol (Dordr). 2019; 43(2):249-261.
PMID: 31884576
DOI: 10.1007/s13402-019-00485-5.
MicroRNA-101 Protects Against Cardiac Remodeling Following Myocardial Infarction via Downregulation of Runt-Related Transcription Factor 1.
Li X, Zhang S, Wa M, Liu Z, Hu S
J Am Heart Assoc. 2019; 8(23):e013112.
PMID: 31766975
PMC: 6912979.
DOI: 10.1161/JAHA.119.013112.
Upregulation of miR-129-5p increases the sensitivity to Taxol through inhibiting HMGB1-mediated cell autophagy in breast cancer MCF-7 cells.
Shi Y, Gong W, Lu L, Wang Y, Ren J
Braz J Med Biol Res. 2019; 52(11):e8657.
PMID: 31664305
PMC: 6826894.
DOI: 10.1590/1414-431X20198657.
Inactivation of the Wnt/β-catenin signaling pathway underlies inhibitory role of microRNA-129-5p in epithelial-mesenchymal transition and angiogenesis of prostate cancer by targeting ZIC2.
Jiang Z, Zhang Y, Chen X, Wu P, Chen D
Cancer Cell Int. 2019; 19:271.
PMID: 31649488
PMC: 6805653.
DOI: 10.1186/s12935-019-0977-9.
Long non-coding RNA NONHSAT101069 promotes epirubicin resistance, migration, and invasion of breast cancer cells through NONHSAT101069/miR-129-5p/Twist1 axis.
Yao N, Fu Y, Chen L, Liu Z, He J, Zhu Y
Oncogene. 2019; 38(47):7216-7233.
PMID: 31444414
DOI: 10.1038/s41388-019-0904-5.
Relation of over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines.
Huang D, Huang Y, Huang Z, Weng J, Zhang S, Gu W
Cancer Cell Int. 2019; 19:166.
PMID: 31244554
PMC: 6582545.
DOI: 10.1186/s12935-019-0885-z.